NCT00416650

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) in Patients With Advanced Bronchioalveolar Cell Lung Cancer.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Vanderbilt-Ingram Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with advanced non-small cell lung cancer.

Detailed description

OBJECTIVES: Primary * Determine the major objective response rate (partial response and complete response) in patients with advanced bronchoalveolar cell non-small cell lung cancer treated with erlotinib hydrochloride. Secondary * Assess the quality of life of patients treated with this regimen. * Determine the duration of response and time to disease progression in patients treated with this regimen. * Determine the median survival of patients treated with this regimen. OUTLINE: This is an open-label, nonrandomized, multicenter study. Patients receive oral erlotinib hydrochloride daily in the absence of disease progression or unacceptable toxicity.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	erlotinib hydrochloride	All patients will receive 150 mg orally daily

Timeline

• Start date: 2002-07-01
• Primary completion: 2007-10-01
• Completion: 2013-03-01
• First posted: 2006-12-28
• Last updated: 2013-04-04

Locations

4 sites across 1 country: United States